Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM09-II
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MM09-II is an investigational subcutaneous allergen immunotherapy (SCIT) developed by Inmunotek, S.L. for the treatment of house dust mite-induced allergic conditions. The product consists of chemically modified (polymerized) allergen extracts derived from two house dust mite species, *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. By utilizing polymerized allergens, also known as allergoids, the therapy aims to reduce IgE-mediated reactivity and the associated risk of systemic side effects while maintaining the immunogenicity required to induce long-term immunological tolerance. MM09-II is currently being evaluated in Phase 2 clinical trials in Spain for patients with moderate to severe allergic rhinitis, rhinoconjunctivitis, and associated asthma who are sensitized to house dust mites.
- Other names
- MM09-IIMM-09-IIMM 09-IIpolymerized house dust mite allergen immunotherapy
02
Targets
HDM-specific IgE (House dust mite-specific immunoglobulin E)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on MM09-II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM09-II.